as I look over the technicals, fundamentals and chart compared to the rest of the group there in, it's bad. As I mentioned before there above there 50 day line which is a postive. However, if it should drop below that 50 day line it could become a resistant point which may be hard to brake through. Biopharm. companies are pretty much know for spending revenues. The payoff is if they come up with something a larger Phamaceutical can profit from in there pipeline as we all know. I have to chuckle to myself when I see a commercial on TV where a drug company trys to sell there product, then they give you all the side affects that could happen....eeks, the side affects are worst than the problem your trying to cure. On a bright note and I'm not sure that I consider it bright because of recent hype before the ICAD meeting which appears to be dwindling. Prana pecentage change year to date is 7 % where the group there in is 1%. There % change in the last 12 months is 59% where the group there in was -1% There % change in the last 4 weeks is 14% where the group as a whole was 13% I won't mention there percentage change against the S&P, but in was slightly up over the group. All this is postive at the moment. The group there in isn't exactly setting the world a blaze either. Prana sure could use financial backing, there market cap is only 77 million.......a slight gust of wind seems to blow this stock up and down the chart. One thing that drives me crazy is the ask/bid on Prana. I realize we have a big time difference and markets from other countries open after New York.......hard to get a handle on how this stock will appear the following morning.
The price movements of Prana stock have been little more than semi-random noise in recent months, aside from the big spike the day of the press release about the Phase IIa results early in the year. The market cap is too small for institutional investors to get very interested in it, and the company is below the radar of Wall Street and of most individual investors. The trading volume is so tiny that a few small buy or sell orders in a given day can sway the price a lot.
But Prana has talent (Drs. Bush and Tanzi are world-renowned Alzheimer's pioneers), and as far as I know they're the only company pursuing the metal-protein angle.
We'll just have to wait for some news and see what happens.